1.Study on weight units of chinese medicine in Sui and Tang dynasties.
Rui-xian ZHANG ; Qin LU ; Wei ZHANG ; Mu-qun ZHANG
China Journal of Chinese Materia Medica 2008;33(17):2201-2204
Although there were changes in measuring system of Sui dynasty, the measuring units of medicine, astronomy and music still remained unchanged. So there appeared two systems of measuring units. For medicine, the government of Tang dynasty followed the regulations of Sui dynasty in measuring system. Besides this, the measuring units of Qian and Fen also were also related to medicine.
China
;
Drugs, Chinese Herbal
;
chemistry
;
standards
;
History, Ancient
;
Medicine, Chinese Traditional
;
history
;
standards
;
Weights and Measures
;
history
;
standards
2.Study on measuring units of Chinese medicine in Wei Jin and Southern and Northern Dynasties.
Rui-xian ZHANG ; Qin LU ; Wei ZHANG ; Mu-qun ZHANG
China Journal of Chinese Materia Medica 2008;33(15):1906-1908
There were some changes for the measuring units of medicine in Wei, Jin and Southern and Northern dynasty. The measuring units of length showed decreased usage in medicine measuring, while increased usage of weight units. Weight unit was also used for measuring medicines that had been measured by imitate unit or assessed unit. Besides, some special measuring units for medicine appeared in this period of time.
Drugs, Chinese Herbal
;
History, Ancient
;
Medicine, Chinese Traditional
;
history
;
methods
3.Outline study on production place of Chinese medicine in Han dynasty.
Rui-xian ZHANG ; Jing WANG ; Wei ZHANG ; Mu-qun ZHANG
China Journal of Chinese Materia Medica 2008;33(14):1776-1781
The administrative area of Han dynasty was basically divided into 13 states. There were very little records about the place of medicine production in literatures. This article tried to outline the basic feature of region of medicine production from the available books of
China
;
Drugs, Chinese Herbal
;
Geography
;
History, Ancient
;
Medicine, Chinese Traditional
;
history
4.Study on other measuring units of Chinese medicine in Sui and Tang dynasties.
Rui-Xian ZHANG ; Qin LU ; Wei ZHANG ; Mu-Qun ZHANG
China Journal of Chinese Materia Medica 2008;33(18):2136-2139
Besides the changes in weight measuring units, the other units also changed. "Larger and smaller liter" affected traditional Chinese medicine. Length measuring units was little used, and the irregular measuring units such as imitate units, quantity units, and assessing units remained in some extent. Because the regular measuring units gradually replaced the irregular ones, some doctors made investigates to the conversion of these measuring units.
History, Ancient
;
Medicine, Chinese Traditional
;
history
;
methods
5.Study on volume and length units of Chinese medicine in song dynasties.
Rui-Xian ZHANG ; Qin LU ; Wei ZHANG ; Mu-Qun ZHANG
China Journal of Chinese Materia Medica 2008;33(21):2574-2576
In the Song dynasties, the irregular measuring units were seldom used in medicine and length units were no longer used in medicine. The volume units changed from "ancient ones" to "modern ones". There were necessary regulations on the conversion of measuring units of medicine in medical books officially published. Doctor Chenyan made detailed investigations to ancient measuring units.
History, Medieval
;
Medicine, Chinese Traditional
;
history
6.Study on measuring units of Chinese medicine in Song dynasties.
Rui-Xian ZHANG ; Qin LU ; Wei ZHANG ; Mu-Qun ZHANG
China Journal of Chinese Materia Medica 2008;33(19):2277-2279
The original changes of the weight measuring unit of medicine in the Song dynasties was the appearance of Dengzi (small steelyard for weighing money). The "larger scale" and "smaller scale" were unified. The measuring unit "qian" was widely used, and furthermore "Cheng" and "zi" were used as measuring units related to medicine.
China
;
History, Medieval
;
Medicine, Chinese Traditional
;
history
;
methods
7.Expression of TGF-beta1 and MMP2 in human renal cell carcinoma and their clinical significance.
Rong-Chao SUN ; Shu-Dong YANG ; Zhuo-Qun XU ; Dong GUO ; Hui-Jun MU ; Qin-He FAN ; Qiang HU ; Li-Hua ZHANG ; Jia-Bei LIANG
Chinese Journal of Pathology 2008;37(3):184-185
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Renal Cell
;
genetics
;
metabolism
;
Female
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Kidney Neoplasms
;
genetics
;
metabolism
;
Male
;
Matrix Metalloproteinase 2
;
genetics
;
metabolism
;
Middle Aged
;
Transforming Growth Factor beta1
;
genetics
;
metabolism
;
Tumor Cells, Cultured
;
Young Adult
8.Nimotuzumab in combination with chemotherapy for patients with malignant gliomas.
Qun-ying YANG ; Dong SHEN ; Ke SAI ; Yong-gao MU ; Xiao-bing JIANG ; Xian-heng ZHANG ; Zhong-ping CHEN
Chinese Journal of Oncology 2011;33(3):232-235
OBJECTIVENimotuzumab is a humanized monoclonal antibody targeted against epidermal growth factor receptor (EGFR). Recent clinical studies show that patients with malignant gliomas could benefit from nimotuzumab treatment. The aim of the present study was to evaluate the efficacy and side effects of nimotuzumab in combination with chemotherapy for patients with malignant gliomas.
METHODSThe patients received 200 mg of nimotuzumab infusion intravenously over 60 minutes once weekly for the first eight weeks and then once every two weeks until unacceptable toxicity or tumor progression occurred. Individualized chemotherapy was administered based on O(6)-methylguanine-DNA methyltransferase (MGMT) expression and previous chemotherapy responses in combined with nimotuzumab.
RESULTSFourteen patients received a total of 122 times of nimotuzumab ranging from 2 to 20 (median 7.5 times). Combined chemotherapy regimens included: continuous 21-day temozolomide (10 cases), standard 5-day temozolomide (2 cases), teniposide plus cisplatin (1 case), and teniposide plus nimustine (1 case). Partial response (PR) and stable disease (SD) were found in 3 patients (21.4%)and 6 patients (42.9%), respectively. Disease control rate (PR + SD) was 64.3%. The median progression-free survival (PFS) was 4 months (95%CI: 0.7 - 7.3) and PFS at 6 months was 30.6%. The most common toxicities include grade I-II neutropenia (2 cases), thrombocytopenia (2 cases), lymphopenia (1 case), nausea and vomitting (3 case) and asymptomatic transaminase increase (1 case). One patient developed grade IV neutropenia and thrombocytopenia. One patient developed nimotuzumab-related acneiform rash.
CONCLUSIONSNimotuzumab in combination with chemotherapy has moderate activity in patients with malignant gliomas and the toxicities are well tolerable, therefore, worth further investigation.
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized ; administration & dosage ; adverse effects ; therapeutic use ; Antineoplastic Agents, Alkylating ; adverse effects ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Astrocytoma ; drug therapy ; Child ; Cisplatin ; administration & dosage ; adverse effects ; Dacarbazine ; adverse effects ; analogs & derivatives ; therapeutic use ; Disease-Free Survival ; Female ; Glioblastoma ; drug therapy ; Glioma ; drug therapy ; Humans ; Infusions, Intravenous ; Male ; Nausea ; chemically induced ; Neutropenia ; chemically induced ; Nimustine ; administration & dosage ; adverse effects ; Teniposide ; administration & dosage ; adverse effects ; Thrombocytopenia ; chemically induced ; Young Adult
9.Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
Qun-Fang GE ; Gui-Fang OUYANG ; Ying CHEN ; Yi ZHANG ; Qi-Tian MU ; Ying LU
Journal of Experimental Hematology 2012;20(1):112-115
This study was purposed to investigate the effect of bortezomib (Bor) and arsenic trioxide (As(2)O(3)) combination on multiple myeloma cell line KM3 and its mechanisms. KM3 cells were cultured with different concentration of Bor or As(2)O(3) as well as both for a certain time. The cell proliferation was analysed by MTT assay and the concentration of 50% proliferation inhibition (IC(50)) was calculated. Early apoptosis and late apoptosis of KM3 cells were detected by Annexin-V-FITC Kit, and the change of transmembrane potential was measured by flow cytometry. mRNA of Caspase-3, Bim and Bcl-xL were detected by RT-PCR. The results showed that the proliferation inhibitory rate of KM3 cells treated by Bor plus As(2)O(3) was much higher than that of KM3 cells treated by Bor only for 72 h [ (27.64 ± 0.81)% vs (21.67 ± 2.20)%, P < 0.05]. There were more KM3 cells treated by Bor plus As(2)O(3) in early apoptosis at 48 h and late apoptosis at 72 h than that of KM3 cells treated only by Bor [ (53.20 ± 3.70)% vs (35.40 ± 2.58)%, P < 0.01; (63.96 ± 2.97)% vs (54.08 ± 3.76)%, P < 0.01]. Transmembrane potential (Δψm) of KM3 cells treated by Bor plus As(2)O(3) decreased more at 48 h, as compared with Bor alone. The expression levels of caspase-3 mRNA and Bim mRNA in KM3 cells treated with Bor plus As(2)O(3) were higher than that in KM3 cells treated with Bor alone. But the expression level of Bcl-xL mRNA was lower than that in KM3 cells treated with Bor alone. It is concluded that As(2)O(3) can enhance the apoptosis-inducing effect of Bor on multiple myeloma cell line KM3, which is associated with decreasing the expression of Bcl-xl mRNA and increasing the expression of Caspase-3 and Bim mRNA.
Apoptosis
;
drug effects
;
Apoptosis Regulatory Proteins
;
metabolism
;
Arsenicals
;
administration & dosage
;
pharmacology
;
Bcl-2-Like Protein 11
;
Boronic Acids
;
administration & dosage
;
pharmacology
;
Bortezomib
;
Caspase 3
;
metabolism
;
Cell Line, Tumor
;
Humans
;
Membrane Proteins
;
metabolism
;
Multiple Myeloma
;
metabolism
;
pathology
;
Oxides
;
administration & dosage
;
pharmacology
;
Proto-Oncogene Proteins
;
metabolism
;
Pyrazines
;
administration & dosage
;
pharmacology
;
bcl-X Protein
;
metabolism
10.Comparative analysis of the risk factor on the clinical information of myocardial revascularization combined with concomitant valve operations.
Jun-sheng MU ; Jian-qun ZHANG ; Ping BO ; Xu MENG ; Cheng-xiong GU ; Fang-jiong HUANG ; Wen-bin LI ; Sheng-yu WANG ; Hong-jia ZHANG
Chinese Journal of Surgery 2006;44(18):1238-1240
OBJECTIVETo evaluate the clinic information of coronary artery bypass grafting (CABG) combined with concomitant valve operation.
METHODSRetrospectively analyze the information of morbidity and mortality of 126 cases patients who underwent combined valve and bypass procedures between December 2000 and January 2005. These patients had been divided into 2 groups according to sex.
RESULTSThere were significant differences in the clinic characteristic such as weight and diabetes mellitus and mitral valve stenosis and three disease vessels of coronary artery between 2 groups (P < 0.05). The rate of the number of bypass grafts and morbidity and mortality of complication were significant differences (P < 0.05). The number of mitral valve replacement of female was more than that of male (P < 0.05). Five males died after operation, 1 case of heart failure, 1 case of high blood sugar, 2 cases of arrhythmia, 2 cases of organs failure; Seven females died after operation, one case of heart failure, one case of alimentary tract haemorrhage, three cases of arrhythmia, two cases of organs failure.
CONCLUSIONSCoronary artery bypass grafting (CABG) combined with concomitant valve operation is safe and effective. The rate of morbidity and mortality of complication of female is more than that of male. The study demonstrates that female gender is an independent risk factor for combined morbidity and mortality during and after combined valve and coronary bypass surgery. That is related to low weight and mitral valve stenosis of female.
Adult ; Aged ; Body Weight ; Coronary Artery Bypass ; Extracorporeal Circulation ; Female ; Heart Valve Prosthesis Implantation ; Humans ; Male ; Middle Aged ; Myocardial Revascularization ; Retrospective Studies ; Risk Factors ; Sex Factors